The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma

Pharmacotherapy

Volumn 17, Issue 1 SUPPL., 1997, Pages

  Sorkness, Christine A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CROMOGLYCATE DISODIUM; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; MONTELUKAST; PRANLUKAST; SALBUTAMOL; ZAFIRLUKAST; ZILEUTON;

ARTICLE; ASTHMA; BLOOD VESSEL PERMEABILITY; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; GASTRITIS; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; PATHOGENESIS; PHARYNGITIS; RHINITIS; SINUSITIS;

ARACHIDONATE 5-LIPOXYGENASE; ASTHMA; CHRONIC DISEASE; HUMANS; LEUKOTRIENE ANTAGONISTS; LIPOXYGENASE INHIBITORS;

EID: 0031025167     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. National Asthma Education Program, Expert Panel Report. Guidelines for the diagnosis and management of asthma. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health publication no. 91-3042, 1991.
2. Henderson WR. The role of leukotrienes in inflammation. Ann Intern Med 1994;121:684-97.
3. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990;323:645-55.
4. 4 on the microvasculature of guinea pigs. Prostaglandins 1981;21:315-21.
5. Yanni JM, Foxwell MH, Whitman LL, Smith WL, Nolan JC. Effect of intravenously administered lipoxygenase metabolites on rat tracheal mucous gel layer thickness. Int Arch Allergy Appl Immunol 1989;90:307-9.
6. 4 is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence. Blood 1981;58:658-63.
7. Dahlen S-E, Hedqvist P, Hammarstrom S, Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature 1980;288:484-6.
8. Israel E, Rubin P, Kemp J, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993;119:1059-66.
9. Pierson WE, LaForce CF, Bell TD, et al. Long-term, double-blind comparison of controlled-release albuterol versus sustained release theophylline in adolescents and adults with asthma. J Allergy Clin Immunol 1990;85:618-26.
10. 4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI-204,219. Clin Pharmacol Therapeut 1993;54:430-6.
11. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150:618-23.
12. Lockey RF, Lavins BJ, Snader L. Effects of 13 weeks of treatment with ICI 204,219 (Accolate™) in patients with mild-to-moderate asthma [abstr]. J Allergy Clin Immunol 1995;95:350.
13. Nathan RA, Glass M, Snader L. Effects of 13 weeks of treatment with ICI 204,219 ('Accolate') or cromolyn sodium ('Intal') in patients with mild to moderate asthma [abstr]. J Allergy Clin Immunol 1995;95:388.
14. Kemp JP, Glass M, Minkwitz MC. Onset of action of the leukotriene-receptor antagonist, zafirlukast (Accolate™), in patients with asthma [abstr]. J Allergy Clin Immunol 1995;95:351.